These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. Pachocki CJ; Hol EM J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059 [TBL] [Abstract][Full Text] [Related]
16. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report. Serrallach BL; Tran BH; Bauer DF; Mohila CA; Adesina AM; McGovern SL; Lindsay HB; Huisman TA Neuroradiol J; 2022 Oct; 35(5):634-639. PubMed ID: 34989626 [TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma. Zhang Q; Yang L; Liu YH; Wilkinson JE; Krainer AR Sci Transl Med; 2023 Apr; 15(691):eadd8280. PubMed ID: 37043556 [TBL] [Abstract][Full Text] [Related]
18. Transcriptomic and proteomic spatial profiling of pediatric and adult diffuse midline glioma H3 K27-Altered. Damodharan S; Shireman JM; Xie E; Distler E; Kendziorski C; Dey M Sci Rep; 2024 Sep; 14(1):22668. PubMed ID: 39349581 [TBL] [Abstract][Full Text] [Related]
19. H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions. Nonnenbroich LF; Bouchal SM; Millesi E; Rechberger JS; Khatua S; Daniels DJ Cells; 2024 Jun; 13(13):. PubMed ID: 38994974 [TBL] [Abstract][Full Text] [Related]